Xilio Therapeutics (NASDAQ:XLO) Issues Earnings Results

Xilio Therapeutics (NASDAQ:XLO) issued its earnings results on Monday. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.68) by $2.49, FiscalAI reports. Xilio Therapeutics had a negative net margin of 183.90% and a negative return on equity of 679.66%. The company had revenue of $13.69 million for the quarter, compared to analyst estimates of $10.90 million.

Xilio Therapeutics Stock Performance

Shares of XLO opened at $7.86 on Monday. The stock has a 50 day simple moving average of $8.05 and a 200 day simple moving average of $9.62. Xilio Therapeutics has a 52-week low of $6.47 and a 52-week high of $16.52. The firm has a market capitalization of $41.27 million, a PE ratio of -0.86 and a beta of -0.05.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xilio Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.00.

Institutional Trading of Xilio Therapeutics

Several hedge funds have recently bought and sold shares of XLO. Bain Capital Life Sciences Investors LLC lifted its stake in Xilio Therapeutics by 61.4% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 7,372,686 shares of the company’s stock valued at $4,720,000 after buying an additional 2,805,869 shares in the last quarter. Ghisallo Capital Management LLC bought a new stake in shares of Xilio Therapeutics during the fourth quarter worth $713,000. Velan Capital Investment Management LP bought a new stake in shares of Xilio Therapeutics during the fourth quarter worth $109,000. State Street Corp raised its holdings in shares of Xilio Therapeutics by 13.7% during the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after acquiring an additional 22,500 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Xilio Therapeutics during the fourth quarter worth $27,000. 54.29% of the stock is currently owned by institutional investors and hedge funds.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.